Fractyl Health, Inc. Common Stock (GUTS) - Total Liabilities
Based on the latest financial reports, Fractyl Health, Inc. Common Stock (GUTS) has total liabilities worth $111.94 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Fractyl Health, Inc. Common Stock equity growth rate to track the company's year-over-year net asset growth rate.
Fractyl Health, Inc. Common Stock - Total Liabilities Trend (2019–2025)
This chart illustrates how Fractyl Health, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data.
Fractyl Health, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Fractyl Health, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Riber S.A
PA:ALRIB
|
France | €27.29 Million |
|
Caravel Minerals Ltd
AU:CVV
|
Australia | AU$901.04K |
|
Shin Heung Energy & Electronics Co.Ltd
KQ:243840
|
Korea | ₩545.48 Billion |
|
Hanmiglobal
KO:053690
|
Korea | ₩209.78 Billion |
|
GR Silver Mining Ltd
V:GRSL
|
Canada | CA$1.16 Million |
|
Fairchem Organics Limited
NSE:FAIRCHEMOR
|
India | Rs1.28 Billion |
|
ADDvise Group B
ST:ADDV-B
|
Sweden | Skr1.81 Billion |
|
Suria Capital Holdings Bhd
KLSE:6521
|
Malaysia | RM258.32 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Fractyl Health, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Fractyl Health, Inc. Common Stock.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.78 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 11.84 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.92 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Fractyl Health, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Fractyl Health, Inc. Common Stock (2019–2025)
The table below shows the annual total liabilities of Fractyl Health, Inc. Common Stock from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | $111.94 Million | +40.54% |
| 2024-09-30 | $79.65 Million | -80.15% |
| 2023-09-30 | $401.27 Million | +28.09% |
| 2022-09-30 | $313.27 Million | +0.45% |
| 2021-09-30 | $311.87 Million | +1474.40% |
| 2020-09-30 | $19.81 Million | -87.05% |
| 2019-09-30 | $152.93 Million | -- |
About Fractyl Health, Inc. Common Stock
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a nove… Read more